Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States.

The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis.

It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes.

In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results.

It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides.

The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013.

The company was founded in 2010 and is headquartered in San Diego, California.